Verastem
Verastem's revenue rose 209.1% to $31 million in fiscal 2025. Its operating margin was −550.3%, up from −1,149.6% a year earlier. The diluted share count rose 94.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Verastem does
Verastem Oncology is a biopharmaceutical company that develops and sells medicines for cancers driven by the RAS/MAPK pathway, a signaling route that helps tumor cells survive and grow. It markets AVMAPKI FAKZYNJA CO-PACK in the United States. The FDA gave it accelerated approval on May 8, 2025 for adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have had earlier systemic therapy.
The company is running RAMP 301, a Phase 3 trial that serves as the confirmatory study for that approval and could widen its use. Its pipeline has clinical-stage programs, preclinical research and early programs with partners. The company focuses on small-molecule drugs, used alone and in combination, that block RAF/MEK, FAK or KRAS G12D. Its lead clinical candidate is VS-7375, an oral KRAS G12D inhibitor tested in pancreatic, lung and colorectal cancers.
It earns revenue from selling its approved medicine. It also has a collaboration with GenFleet Therapeutics on early assets. Its products are still in clinical testing for other cancers.
Its biggest risks, as it describes them
- Delays in enrolling patients in clinical trials, which could delay approvals.
- Its targeted cancer drugs use an emerging science that may not work as expected.
- The market for its approved medicine and other candidates may be smaller than it estimates.
- Substantial competition from companies that may reach the market first or do better.
- Serious side effects found in testing, or failure to get approval outside the United States.
Income statement
Verastem lost money in fiscal 2025: a net loss of $210 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 100 | 88 | 137 | 89 | 205 |
| Debt incl. finance leases | 0 | 24 | 40 | 41 | — |
| Net debt (negative means net cash) | −100 | −63 | −97 | −48 | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.5x | 0.7x | — | — |
| Interest coverage | −6.2x | −34.1x | −22.2x | −25.2x | −149.5x |
| Current ratio | 5.7x | 4.3x | 5.5x | 3.1x | 3.1x |
| Quick ratio | 5.7x | 4.3x | 5.5x | 3.1x | 3.1x |
Cash flow
Projections
Project Verastem's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Verastem reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | −16.11 | −34.38 | −15.71 |
| Accruals ratio | −0.7% | −20.6% | −41.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Pass |
| F-score | — | — | — |
Compare
Put Verastem side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Verastem | FY25 | 209.1% | −550.3% | — | — | — | — | |
| Alumis | FY25 | — | −1,886.9% | −1,539.2% | — | — | — | Compare |
| Aquestive Therapeutics | FY25 | −22.6% | −159.5% | −119.0% | — | — | 2 | Compare |
| Ocular Therapeutix | FY25 | −18.5% | −519.8% | −417.5% | — | — | 4 | Compare |
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | 27 | 18 | 88 | 2 | 3 | — | 10 | 31 |
| Revenue growth | — | — | — | −34.7% | 407.1% | −97.7% | 26.4% | — | — | 209.1% |
| Gross profit | — | — | 27 | — | — | — | — | — | — | — |
| Research and development | 20 | 46 | 44 | 46 | 41 | 39 | 51 | 61 | 81 | 115 |
| Operating income | −37 | −68 | −95 | −132 | −49 | −61 | −73 | −92 | −115 | −170 |
| Net income | −36 | −68 | −72 | −149 | −68 | −71 | −74 | −87 | −131 | −210 |
| Diluted EPS (US$) | −0.99 | −1.76 | −1.37 | −2.00 | −0.44 | −4.90 | −4.57 | −3.96 | −3.66 | −3.02 |
| Diluted shares (millions) | 37 | 38 | 69 | 75 | 0 | 14 | 16 | 22 | 36 | 69 |
| Cash flow | ||||||||||
| Cash from operations | −30 | −57 | −74 | −138 | −34 | −54 | −64 | −86 | −105 | −138 |
| Capital expenditure | 0 | — | 2 | 0 | 0 | 0 | — | — | 0 | — |
| Free cash flow | −30 | — | −76 | −139 | −34 | −54 | — | — | −105 | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 6 | 5 | 7 | 8 | 8 | 8 | 6 | 6 | 7 | 9 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 81 | 87 | 250 | 111 | 148 | 100 | 88 | 137 | 89 | 205 |
| Debt incl. finance leases | — | 15,000 | 95 | 69 | 19 | 0 | 24 | 40 | 41 | — |
| Total assets | 84 | 90 | 277 | 145 | 154 | 109 | 95 | 150 | 102 | 246 |
| Total liabilities | 11 | 32 | 153 | 138 | 39 | 21 | 48 | 71 | 130 | 189 |
| Shareholders' equity | 72 | 58 | 124 | 7 | 115 | 88 | 47 | 57 | −29 | 57 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | 99.4% | — | — | — | — | — | — | — |
| Operating margin | — | — | −354.8% | −758.1% | −55.8% | −2,991.2% | −2,809.6% | — | −1,149.6% | −550.3% |
| Net margin | — | — | −271.1% | −854.8% | −76.5% | −3,468.1% | −2,843.3% | — | −1,306.4% | −677.6% |
| Free cash flow margin | — | — | −284.5% | −793.6% | −37.9% | −2,615.6% | — | — | −1,048.0% | — |
| Rule of 40 (growth + FCF margin) | — | — | — | −828.2% | 369.2% | −2,713.3% | — | — | — | — |
| Return on capital | — | — | −1.0% | — | — | — | — | — | — | — |
| Return on equity | −41.7% | −104.3% | −79.6% | −227.0% | −110.6% | −70.2% | −109.4% | −166.8% | −917.4% | −1,480.2% |
| Return on assets | −37.0% | −78.2% | −39.5% | −70.7% | −45.2% | −54.1% | −72.5% | −71.4% | −104.0% | −120.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |